Nasdaq Nnvc

• NanoViricides, Inc. (NASDAQ:NNVC) has announced the launch of a Phase II clinical trial for NV-387, an oral gummy treatment designed to combat Ebola viruses. • The trial is being conducted in the Democratic Republic of the Congo (DRC) and is led by Prof. Patrick Katoto, a distinguished researcher and Fogarty Fellow. • This medical intervention is a direct response to the growing Bundibugyo outbreak, aiming to provide a scalable treatment option in a high-risk region.

• NanoViricides, Inc. (NASDAQ:NNVC) has received regulatory approval to initiate a Phase II Clinical Trial for NV-387 oral gummies. • The drug is being developed as a treatment for the Bundibugyo Ebola virus, addressing an urgent need for effective antivirals during the current outbreak in the Democratic Republic of the Congo. • This trial offers a potentially faster alternative to the PARTNERS clinical trial, which requires over 1,000 patients and may take more than a year to yield results.

• NanoViricides, Inc. (NASDAQ:NNVC) has received regulatory approval to initiate a Phase II Clinical Trial for NV-387 oral gummies designed to treat the Bundibugyo Ebola virus. • The trial addresses an urgent need for effective antiviral drugs amid a current outbreak in the Democratic Republic of Congo (DRC). • This development is critical because existing FDA-approved antibody drugs for EBOV Zaire are not considered effective for the Bundibugyo strain without further testing.